| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 07/02/2002 | US6413740 Nucleic acid which codes for muscle specific kinase c-terminal fragment of human agrin; diagnosis and treatment of muscle disorders and neuromusclar disorders |
| 07/02/2002 | US6413735 Method of screening for a modulator of angiogenesis |
| 07/02/2002 | US6413731 Methods of screening for compounds which bind to a human SNORF36A receptor |
| 07/02/2002 | US6413719 KCNQ2 and KCNQ3-potassium channel genes which are mutated in benign familial neonatal convulsions (BFNC) and other epilepsies |
| 07/02/2002 | US6413544 Sandwich liposome comprises biologically active agents internalized between two bilomellar liposomes; 1,2-bis(oleoyloxy)-3-(trimethylammonio)-propane chloride, cholesterol or cholesterol derivative |
| 07/02/2002 | US6413543 Phosphatidyl oligoglycerols |
| 07/02/2002 | US6413524 spsA polynucleotides and polypeptides |
| 07/02/2002 | US6413522 Papilloma viruses, products for the detection thereof as well as for treating diseases caused by them |
| 07/02/2002 | US6413517 Identification of broadly reactive DR restricted epitopes |
| 07/02/2002 | US6413516 Suppression lymphocytes |
| 07/02/2002 | US6413511 Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide |
| 07/02/2002 | CA2184908C Human osteoclast-derived cathepsin |
| 06/27/2002 | WO2002050288A1 Neocentromere-based mini-chromosomes or artificial chromosomes |
| 06/27/2002 | WO2002050284A2 Oxidoreductases |
| 06/27/2002 | WO2002050278A2 Novel human secreted proteins and polynucleotides encoding the same |
| 06/27/2002 | WO2002050269A1 Method of examining allergic disease |
| 06/27/2002 | WO2002050263A2 Methods_for treating tissue damage by bone-marrow derived stem cells |
| 06/27/2002 | WO2002050243A2 The use of ecm degrading enzymes for the improvement of cell transplantation |
| 06/27/2002 | WO2002050122A2 Means for the diagnosis and therapy of ctcl |
| 06/27/2002 | WO2002050115A1 Modified tachykinin receptors |
| 06/27/2002 | WO2002050106A2 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r4 |
| 06/27/2002 | WO2002050105A1 Novel compounds |
| 06/27/2002 | WO2002050096A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | WO2002049714A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049677A1 Lentiviral vector-mediated gene transfer and uses thereof |
| 06/27/2002 | WO2002049676A2 Compositions containing inclusion complexes |
| 06/27/2002 | WO2002049669A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049664A1 Direct delivery of a gene product to the hypothalamus |
| 06/27/2002 | WO2002049625A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | WO2002049501A2 Local regional chemotherapy and radiotherapy using in situ hydrogel |
| 06/27/2002 | WO2002049423A1 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus |
| 06/27/2002 | WO2002049422A2 Non-human animal disease models |
| 06/27/2002 | WO2002024730A3 Transduction of dendritic cells using adenoviral vectors |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020721A3 Vectors derived from south african arbovirus no. 86 |
| 06/27/2002 | WO2002016548A3 Novel g protein-coupled receptor |
| 06/27/2002 | WO2001098536A3 METHOD FOR ACTIVATING PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-$g(g) |
| 06/27/2002 | WO2001094570A3 Transfection method |
| 06/27/2002 | WO2001087938A3 Polynucleotide sequence encoding a putative cell adhesion molecule |
| 06/27/2002 | WO2001081361B1 Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death |
| 06/27/2002 | WO2001077375A3 Diagnosis of diseases associated with gene regulation |
| 06/27/2002 | WO2001075092A3 CpG REDUCED PLASMIDS AND VIRAL VECTORS |
| 06/27/2002 | WO2001073027A3 Compositions and methods for therapy and diagnosis of colon cancer |
| 06/27/2002 | WO2001073025A3 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 06/27/2002 | WO2001072994A3 Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
| 06/27/2002 | WO2001070978A3 Polypeptides and nucleic acids encoding same |
| 06/27/2002 | WO2001070276A3 Aav5 vector for transducing brain cells and lung cells |
| 06/27/2002 | WO2001014536A3 Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence |
| 06/27/2002 | WO2000071561A9 Cd4-independent hiv envelope proteins as vaccines and therapeutics |
| 06/27/2002 | WO2000069879A9 Ca7 cg04 gene |
| 06/27/2002 | WO2000050008A9 Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| 06/27/2002 | US20020083489 DNA molecules and polypeptides of pseudomonas syringae Hrp pathogenicity island and their uses |
| 06/27/2002 | US20020083479 Insertion of nucleotide sequences into genome of germ cells; obtain gonads, incubate with transfection mixture, allow insertion, monitor cells for preferential marker |
| 06/27/2002 | US20020083477 Treating nerve damage; administer insulin like growth factor isoform to human, monitor response of damaged nerves |
| 06/27/2002 | US20020082415 Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression |
| 06/27/2002 | US20020082413 PGC-1, a novel brown fat PPARgamma coactivator |
| 06/27/2002 | US20020082412 Methods |
| 06/27/2002 | US20020082408 GSK3 polypeptides |
| 06/27/2002 | US20020082406 Novel human kinase interacting protein and polynucleotides encoding the same |
| 06/27/2002 | US20020082402 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 06/27/2002 | US20020082392 Antibodies to cell-cycle regulatory proteins, and uses related thereto |
| 06/27/2002 | US20020082388 Polypeptide for use in the treatment, diagnosis and prevention of cancer, nervous system and developmental disorders |
| 06/27/2002 | US20020082385 Protein for use in dietetics and the treatment of diabebtes |
| 06/27/2002 | US20020082237 Complexing a cationic polymer and/or cationic lipid with a polynucleotide in the presence of detergent, removing the detergent whereby a stable polynucleotide dellivery vehicle is produced |
| 06/27/2002 | US20020082236 A double stranded nucleic acid molecules with a first strand comprises an RNA sequence which codes for a protein of interest linked downstream of a flanking sequence and a translation initiation site inserted upstream of the RNA |
| 06/27/2002 | US20020082234 Novel prokaryotic polynucleotides, polypeptides and their uses |
| 06/27/2002 | US20020082231 Utilizing ratC polypeptides to screen for antibacterial compounds |
| 06/27/2002 | US20020082230 Introducing an antisense oligomer into a cell, allowing the oligomer to hybridize to the mRNA of IL-15, thereby inhibiting the production of IL-15 |
| 06/27/2002 | US20020082229 ErbB4 receptor-specific neuregulin related ligands and uses therefor |
| 06/27/2002 | US20020082228 Specific oligonucleotides (8-50 nucleobses) hybridize with nucleic acids encoding BH3 Interacting domain Death agonist |
| 06/27/2002 | US20020082227 An ester linkage moieties of the oligonucleotide is replaced with a thioate linkage, such as phosphrothioates, useful as therapies for treating abnormal/undesirable conditions which can arise as a result of complement activation |
| 06/27/2002 | US20020082226 Antisense antibacterial method and composition |
| 06/27/2002 | US20020082224 Non-immunogenic prodrugs and selectable markers for use in gene therapy |
| 06/27/2002 | US20020082217 Synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes |
| 06/27/2002 | US20020082205 Human FGF-23 gene and gene expression products |
| 06/27/2002 | US20020082203 Novel sphingosine kinases |
| 06/27/2002 | US20020081739 Genetically engineering cells; obtain cell, obtain nucleotide sequences, adhere sequences to sheets, propel sheet into cells, recover transformed cells |
| 06/27/2002 | US20020081736 Transferring nucleotide sequences into cells; generate mixture of dextrin, sucrose and nucleotide sequences, incubate with cell, recover transformed cells |
| 06/27/2002 | US20020081733 Method to prepare drug-resistant, non-malignant hematopoietic cells |
| 06/27/2002 | US20020081711 Expression vector for use in the reatment of solid tumors |
| 06/27/2002 | US20020081710 Purification of preferential viral particles; obtain solution containing viral particles, mix with polyelectrolyte, centrifuge, recover pellet, separate viral particles from pellet |
| 06/27/2002 | US20020081709 Expression vector for use as tool in genetic engineering |
| 06/27/2002 | US20020081706 Negative strand rna viral vector having autonomous replication capability |
| 06/27/2002 | US20020081682 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of bacterial infections |
| 06/27/2002 | US20020081680 Fusion protein for use in the diagnosis and treatment of tumors |
| 06/27/2002 | US20020081664 Expression and export of interferon-alpha proteins as Fc fusion proteins |
| 06/27/2002 | US20020081659 Nucleic acids, proteins and antibodies |
| 06/27/2002 | US20020081654 Targeting hydrolase enzymes |
| 06/27/2002 | US20020081647 Apoptosis inducing molecule ii and methods of use |
| 06/27/2002 | US20020081644 Encoded by a polynucleotide; use as reporter molecule |
| 06/27/2002 | US20020081633 Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
| 06/27/2002 | US20020081613 Detecting cancer in a tissue sample; obtain tissue sample, screen for preferential marker, presence of marker indicates cancer |
| 06/27/2002 | US20020081607 Four disulfide core domain-containing (FDCD) polynucleotides, polypeptides, and antibodies |
| 06/27/2002 | US20020081605 Method for detecting growth hormone variations in humans, the variations and their uses |
| 06/27/2002 | US20020081601 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 06/27/2002 | US20020081578 Nucleotide sequences coding preferential polypeptide for as anticarcinogenic agents |
| 06/27/2002 | US20020081568 Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds |
| 06/27/2002 | US20020081299 Hair cell disorders |
| 06/27/2002 | US20020081297 Co-administering to the mammal a recombinant virus comprising a transgene and an immune modulator which inhibits the formation of neutralizing antibodies to the recombinant virus |
| 06/27/2002 | US20020081288 A polypeptide selected from the group consisting of a SOD-4 polypeptide (superoxide dimutase) having a preferred deduced amino acid sequence and fragments, analogs and derivatives encoded by a specific polynucleotide |